目的：探讨多西他赛(艾素)每周给药联合卡铂治疗晚期非小细胞肺癌的临床疗效和不良反应。
Objective: To investigate the efficacy and safety of docetaxel administrated weekly plus carboplatin in the treatment of patients with advanced non-small-cell lung cancer (NSCLC).
结论力扑素联合卡铂治疗晚期卵巢上皮癌近期疗效确切，毒副反应较多帕菲联合卡铂化疗轻，值得临床进一步研究观察。
Conclusionspaclitaxel liposome plus carboplatin in advanced epithelial ovarian cancer is effective, toxicity than docetaxel and carboplatin chemotherapy in light observation worthy of further study.
目的观察置管引流后卡铂灌注化疗联合ep方案治疗妇科恶性腹水的临床近期疗效。
Objective to observe the closer clinical curative effects of controlling gynecological malignant ascites by ep chemotherapy combined with Carboplatin intraperitoneal chemotherapy after duct deposited.
连续的化学治疗临床试验显示顺铂(或卡铂)加紫杉醇是已经证实最有效的联合。
Sequential clinical trials of chemotherapy agents demonstrate that cisplatin (or carboplatin) given in combination with paclitaxel is the most active combination identified.
目的：探讨泰素加卡铂联合化疗方案对非小细胞肺癌的疗效。
Objective:To investigate the efficacy of treating taxol plus carboplatin in the treatment of non-small cell lung cancer.
结论：泰素加卡铂联合化疗方案对中晚期非小细胞肺癌有较好疗效，不良反应小。
Conclusion: the efficacy of treating intermediate and late non-small cell lung cancer with combined taxol and carboplatin chemotherapy is fairly good. The adverse reactions are mild and tolerable.
结论：紫杉醇、顺铂、卡培他滨三药联合一线治疗晚期胃腺癌的疗效和安全性均好。
Conclusions: Paclitaxel combined with cisplatin and capecitabine as the first-line treatment in patients with advanced gastric adenocarcinoma is safe and effective.
结论：紫杉醇、顺铂、卡培他滨三药联合一线治疗晚期胃腺癌的疗效和安全性均好。
Conclusions: Paclitaxel combined with cisplatin and capecitabine as the first-line treatment in patients with advanced gastric adenocarcinoma is safe and effective.
应用推荐